Cargando…
The Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in China
BACKGROUND: More than half of intravenous drug users (IDUs) in China suffer from the Hepatitis C virus (HCV). The virus is also more prevalent in non-injection drug users (NIDUs) than in the general population. However, not much is known about HCV subtype distribution in these populations. METHODS:...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4605846/ https://www.ncbi.nlm.nih.gov/pubmed/26466103 http://dx.doi.org/10.1371/journal.pone.0140263 |
_version_ | 1782395269832245248 |
---|---|
author | Tao, Jun Liang, Jun Zhang, Hui Pei, Lijian Qian, Han-zhu Chambers, Matthew C. Jiang, Yan Xiao, Yao |
author_facet | Tao, Jun Liang, Jun Zhang, Hui Pei, Lijian Qian, Han-zhu Chambers, Matthew C. Jiang, Yan Xiao, Yao |
author_sort | Tao, Jun |
collection | PubMed |
description | BACKGROUND: More than half of intravenous drug users (IDUs) in China suffer from the Hepatitis C virus (HCV). The virus is also more prevalent in non-injection drug users (NIDUs) than in the general population. However, not much is known about HCV subtype distribution in these populations. METHODS: Our research team conducted a cross-sectional study in four provinces in China. We sampled 825 IDUs and 244 NIDUs (1162 total), genotyped each DU’s virus, and performed a phylogenetic analysis to differentiate HCV subtypes. RESULTS: Nucleic acid testing (NAT) determined that 82% percent (952/1162) of samples were HCV positive; we subtyped 90% (859/952) of these. We found multiple HCV subtypes: 3b (249, 29.0%), 3a (225, 26.2%), 6a (156, 18.2%), 1b (137, 15.9%), 6n (50, 5.9%), 1a (27, 3.1%), and 2a (15, 1.7%). An analysis of subtype distributions adjusted for province found statistically significant differences between HCV subtypes in IDUs and NIDUs. DISCUSSION: HCV subtypes 3b, 3a, 6a, and 1b were the most common in our study, together accounting for 89% of infections. The subtype distribution differences we found between IDUs and NIDUs suggested that sharing syringes was not the most likely pathway for HCV transmission in NIDUs. However, further studies are needed to elucidate how NIDUs were infected. |
format | Online Article Text |
id | pubmed-4605846 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-46058462015-10-29 The Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in China Tao, Jun Liang, Jun Zhang, Hui Pei, Lijian Qian, Han-zhu Chambers, Matthew C. Jiang, Yan Xiao, Yao PLoS One Research Article BACKGROUND: More than half of intravenous drug users (IDUs) in China suffer from the Hepatitis C virus (HCV). The virus is also more prevalent in non-injection drug users (NIDUs) than in the general population. However, not much is known about HCV subtype distribution in these populations. METHODS: Our research team conducted a cross-sectional study in four provinces in China. We sampled 825 IDUs and 244 NIDUs (1162 total), genotyped each DU’s virus, and performed a phylogenetic analysis to differentiate HCV subtypes. RESULTS: Nucleic acid testing (NAT) determined that 82% percent (952/1162) of samples were HCV positive; we subtyped 90% (859/952) of these. We found multiple HCV subtypes: 3b (249, 29.0%), 3a (225, 26.2%), 6a (156, 18.2%), 1b (137, 15.9%), 6n (50, 5.9%), 1a (27, 3.1%), and 2a (15, 1.7%). An analysis of subtype distributions adjusted for province found statistically significant differences between HCV subtypes in IDUs and NIDUs. DISCUSSION: HCV subtypes 3b, 3a, 6a, and 1b were the most common in our study, together accounting for 89% of infections. The subtype distribution differences we found between IDUs and NIDUs suggested that sharing syringes was not the most likely pathway for HCV transmission in NIDUs. However, further studies are needed to elucidate how NIDUs were infected. Public Library of Science 2015-10-14 /pmc/articles/PMC4605846/ /pubmed/26466103 http://dx.doi.org/10.1371/journal.pone.0140263 Text en © 2015 Tao et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Tao, Jun Liang, Jun Zhang, Hui Pei, Lijian Qian, Han-zhu Chambers, Matthew C. Jiang, Yan Xiao, Yao The Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in China |
title | The Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in China |
title_full | The Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in China |
title_fullStr | The Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in China |
title_full_unstemmed | The Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in China |
title_short | The Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in China |
title_sort | molecular epidemiological study of hcv subtypes among intravenous drug users and non-injection drug users in china |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4605846/ https://www.ncbi.nlm.nih.gov/pubmed/26466103 http://dx.doi.org/10.1371/journal.pone.0140263 |
work_keys_str_mv | AT taojun themolecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT liangjun themolecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT zhanghui themolecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT peilijian themolecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT qianhanzhu themolecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT chambersmatthewc themolecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT jiangyan themolecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT xiaoyao themolecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT taojun molecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT liangjun molecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT zhanghui molecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT peilijian molecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT qianhanzhu molecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT chambersmatthewc molecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT jiangyan molecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina AT xiaoyao molecularepidemiologicalstudyofhcvsubtypesamongintravenousdrugusersandnoninjectiondrugusersinchina |